Cargando…
Elevated serum levels of S100 and survival in metastatic malignant melanoma.
Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant melanoma seen at our institution be...
Autores principales: | Buer, J., Probst, M., Franzke, A., Duensing, S., Haindl, J., Volkenandt, M., Wittke, F., Hoffmann, R., Ganser, A., Atzpodien, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228235/ https://www.ncbi.nlm.nih.gov/pubmed/9155061 |
Ejemplares similares
-
Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
por: Franzke, A., et al.
Publicado: (1998) -
Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
por: Hoffmann, R, et al.
Publicado: (1999) -
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998) -
Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
por: Wittke, F, et al.
Publicado: (1999) -
Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)